Physician profile
Martin M Grajower
NPI 1538245824
$713,062.04
in general payments reported to CMS, 2019-2025
47 companies · $102K in 2025
The $102K reported for 2025 was more than what 98% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86K · 2020: $70K · 2021: $102K · 2022: $117K · 2023: $108K · 2024: $130K · 2025: $102K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $263K · Consulting Fee: $42K · Travel and Lodging: $24K · Food and Beverage: $10K · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $263,383.62 |
| Consulting Fee | $41,619.97 |
| Travel and Lodging | $23,822.55 |
| Food and Beverage | $10,358.75 |
| Education | $119.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $409,291.10 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $144,861.82 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Echosens North America, INC. | $74,277.10 | 2021-2025 | Fibroscan, Fibroscan |
| Bayer Healthcare Pharmaceuticals INC. | $64,264.39 | 2021-2025 | |
| Abbott Laboratories | $9,376.03 | 2020-2025 | Freestyle Libre |
| Quidel Corporation | $2,500.00 | 2021 | |
| Amgen INC. | $1,169.84 | 2019-2025 | Evenity, Prolia, Tepezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $848.42 | 2019-2025 | Jardiance |
| Amneal Pharmaceuticals LLC | $774.16 | 2020-2025 | Unithroid |
| Astrazeneca Pharmaceuticals Lp | $763.60 | 2019-2023 | Farxiga |
| Abbvie INC. | $744.00 | 2019-2025 | |
| Astellas Pharma US INC | $598.16 | 2019-2023 | Veozah, Myrbetriq |
| Sanofi-Aventis U.S. LLC | $461.15 | 2020-2025 | |
| Radius Health, INC. | $330.87 | 2020-2025 | Tymlos, Binosto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $297.36 | 2019-2024 | Cycloset |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $269.19 | 2021-2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $235.76 | 2022-2025 | |
| Ascendis Pharma Endocrinology INC | $174.68 | 2025 | Yorvipath |
| Esperion Therapeutics, INC. | $171.04 | 2021-2025 | Nexletol |
| Madrigal Pharmaceuticals | $165.29 | 2024-2025 | Rezdiffra, Resmetirom |
| Glaxosmithkline, LLC. | $154.88 | 2021-2024 | Trelegy Ellipta |
| Amarin Pharma, INC. | $124.66 | 2019-2022 | |
| Recordati_rare_diseases_inc. | $112.56 | 2023-2025 | Isturisa, Signifor Lar |
| Janssen Pharmaceuticals, INC | $109.50 | 2019-2020 | |
| Ibsa Pharma INC. | $107.67 | 2021-2023 | Tirosint, Licart |
| Ironwood Pharmaceuticals, INC | $107.18 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $94.60 | 2024-2025 | Recorlev |
| Merck Sharp & Dohme LLC | $74.54 | 2019 | |
| Dexcom, INC. | $68.33 | 2021-2025 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $67.49 | 2023 | Quviviq |
| Tandem Diabetes Care, INC. | $55.28 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Currax Pharmaceuticals LLC | $52.52 | 2020-2021 | |
| Nevro Corp. | $43.44 | 2021-2022 | |
| Insulet Corporation | $41.65 | 2019 | |
| Mannkind Corporation | $34.72 | 2021 | |
| Almatica Pharma LLC | $32.66 | 2025 | Loreev Xr |
| Neurocrine Biosciences, INC. | $26.94 | 2024 | |
| Sandoz INC. | $25.50 | 2025 | |
| Horizon Therapeutics Plc | $22.90 | 2022 | |
| Amryt Pharma Holdings Ltd | $19.96 | 2023 | Mycapssa |
| Ultragenyx Pharmaceutical INC. | $18.86 | 2019 | |
| Medtronic, INC. | $17.49 | 2022 | |
| Vivus LLC | $16.89 | 2019 | |
| Arkray USA, INC. | $16.69 | 2023 | |
| Cequr Corporation | $15.92 | 2022 | |
| Sanofi Pasteur INC. | $13.63 | 2025 | |
| Allergan, INC. | $11.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Grajower listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.